Agonist-biased signaling at the histamine H4 receptor: JNJ7777120 recruits β-arrestin without activating G proteins

Molecular Pharmacology

Volumn 79, Issue 4, 2011, Pages 749-757

  Rosethorne, Elizabeth M ^a   Charlton, Steven J ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 CHLORO 2 INDOLYLCARBONYL) 4 METHYLPIPERAZINE; BETA ARRESTIN; CLOBENPROPIT; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); HISTAMINE; HISTAMINE H4 RECEPTOR; MEPYRAMINE; MITOGEN ACTIVATED PROTEIN KINASE; RANITIDINE; SULFUR 35; THIOPERAMIDE; TRIPROLIDINE;

ARTICLE; BINDING AFFINITY; DRUG ACTIVITY; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; IC 50; PRIORITY JOURNAL;

ARRESTINS; CELL LINE; GTP-BINDING PROTEINS; HUMANS; INDOLES; PIPERAZINES; PROTEIN BINDING; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, HISTAMINE; SIGNAL TRANSDUCTION;

EID: 79953006585     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.068395     Document Type: Article

References (41)

1. Ahn S, Shenoy SK, Wei H, and Lefkowitz RJ (2004) Differential kinetic and spatial patterns of β-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. J Biol Chem 279:35518-35525. (Pubitemid 39100552)
2. Baker JG, Hall IP, and Hill SJ (2002) Pharmacological characterization of CGP 12177 at the human beta(2)-adrenoceptor. Br J Pharmacol 137:400-408.
3. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, and Clarke WP (1998) Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54:94-104. (Pubitemid 28337591)
4. Bokoch MP, Zou Y, Rasmussen SG, Liu CW, Nygaard R, Rosenbaum DM, Fung JJ, Choi HJ, Thian FS, Kobilka TS, et al. (2010) Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. Nature 463:108-112.
5. Bradford MM (1976) A rapid and sensitive method for quantitation of microgram quantities of protein utilizing principle of protein-dye binding. Anal Biochem 72:248-254.
6. Cordeaux Y, Briddon SJ, Megson AE, McDonnell J, Dickenson JM, and Hill SJ (2000) Influence of receptor number on functional responses elicited by agonists acting at the human adenosine A(1) receptor: evidence for signaling pathway-dependent changes in agonist potency and relative intrinsic activity. Mol Pharmacol 58:1075-1084.
7. Cordeaux Y, Nickolls SA, Flood LA, Graber SG, and Strange PG (2001) Agonist regulation of D2 dopamine receptor/G protein interaction. J Biol Chem 276:28667-28675.
8. DeWire SM, Ahn S, Lefkowitz RJ, and Shenoy SK (2007) Beta-arrestins and cell signaling. Annu Rev Physiol 69:483-510.
9. Dowling MR and Charlton SJ (2006) Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M-3 receptor. Br J Pharmacol 148:927-937. (Pubitemid 44543610)
10. Dunford PJ, O'Donnell N, Riley JP, Williams KN, Karlsson L, and Thurmond RL (2006) The histamine H4 receptor mediates allergic airway inflammation by regulating the activation of CD4+ T cells. J Immunol 176:7062-7070. (Pubitemid 43787887)
11. Gay EA, Urban JD, Nichols DE, Oxford GS, and Mailman RB (2004) Functional selectivity of D2 receptor ligands in a chinese hamster ovary hD2L cell line: evidence for induction of ligand-specific receptor states. Mol Pharmacol 66:97-105. (Pubitemid 38822091)
12. Gbahou F, Vincent L, Humbert-Claude M, Tardivel-Lacombe J, Chabret C, and Arrang JM (2006) Compared pharmacology of human histamine H3 and H4 receptors: structure-activity relationships of histamine derivatives. Br J Pharmacol 147:744-754.
13. Gutzmer R, Mommert S, Gschwandtner M, Zwingmann K, Stark H, and Werfel T (2009) The histamine H4 receptor is functionally expressed on TH2 cells. J Allergy Clin Immunol 123:619-625.
14. Hofstra CL, Desai PJ, Thurmond RL, and Fung-Leung WP (2003) Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells. J Pharmacol Exp Ther 305:1212-1221. (Pubitemid 36618001)
15. Jablonowski JA, Grice CA, Chai W, Dvorak CA, Venable JD, Kwok AK, Ly KS, Wei J, Baker SM, Desai PJ, et al. (2003) The first potent and selective non-imidazole human histamine H4 receptor antagonists. J Med Chem 46:3957-3960. (Pubitemid 37122442)
16. Kenakin T (2001) Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 15:598-611.
17. Kenakin T (2005) New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat Rev Drug Discov 4:919-927.
18. Kenakin T (2009) System effects on agonist response: full and partial agonists, in A Pharmacology Primer, 3rd ed. pp 26-9, Elsevier Academic Press, London, UK.
19. Kenakin T and Miller LJ (2010) Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 62:265-304.
20. i3. Mol Pharmacol 71:1349-1359.
21. Lefkowitz RJ and Shenoy SK (2005) Transduction of receptor signals by β-arrestins. Science 308:512-517.
22. Lim HD, van Rijn RM, Ling P, Bakker RA, Thurmond RL, and Leurs R (2005) Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist. J Pharmacol Exp Ther 314:1310-1321. (Pubitemid 41205997)
23. Ling P, Ngo K, Nguyen S, Thurmond RL, Edwards JP, Karlsson L, and Fung-Leung WP (2004) Histamine H4 receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule upregulation. Br J Pharmacol 142:161-171. (Pubitemid 38698205)
24. Liu C, Ma X, Jiang X, Wilson SJ, Hofstra CL, Blevitt J, Pyati J, Li X, Chai W, Carruthers N, et al. (2001) Cloning and pharmacological characterization of a fourth histamine receptor (H4) expressed in bone marrow. Mol Pharmacol 59:420-426. (Pubitemid 32179918)
25. Lohse MJ, Benovic JL, Codina J, Caron MG, and Lefkowitz RJ (1990) Beta-arrestin: a protein that regulates beta-adrenergic receptor function. Science 248:1547-1550.
26. McGuinness D, Malikzay A, Visconti R, Lin K, Bayne M, Monsma F, and Lunn CA (2009) Characterizing cannabinoid CB2 receptor ligands using DiscoveRx Path-Hunter β-arrestin assay. J Biomol Screen 14:49-58.
27. Morse KL, Behan J, Laz TM, West RE Jr, Greenfeder SA, Anthes JC, Umland S, Wan Y, Hipkin RW, Gonsiorek W, et al. (2001) Cloning and characterization of a novel human histamine receptor. J Pharmacol Exp Ther 296:1058-1066. (Pubitemid 32187382)
28. Nakamura T, Itadani H, Hidaka Y, Ohta M, and Tanaka K (2000) Molecular cloning and characterization of a new human histamine receptor, HH4R. Biochem Biophys Res Commun 279:615-620. (Pubitemid 32016763)
29. Oda T, Morikawa N, Saito Y, Masuho Y, and Matsumoto S (2000) Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J Biol Chem 275:36781-36786. (Pubitemid 32002087)
30. Olson KR and Eglen RM (2007) Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol 5:137-144. (Pubitemid 46581247)
31. Pitcher J, Lohse MJ, Codina J, Caron MG, and Lefkowitz RJ (1992) Desensitization of the isolated beta 2-adrenergic receptor by beta-adrenergic receptor kinase, cAMP-dependent protein kinase, and protein kinase C occurs via distinct molecular mechanisms. Biochemistry 31:3193-3197.
32. Rajagopal S, Rajagopal K, and Lefkowitz RJ (2010) Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov 9:373-386.
33. Semple G, Skinner PJ, Gharbaoui T, Shin YJ, Jung JK, Cherrier MC, Webb PJ, Tamura SY, Boatman PD, Sage CR, et al. (2008) 3-(1H-Tetrazol-5-yl)-1,4,5,6- tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice. J Med Chem 51:5101-5108.
34. Shenoy SK, Drake MT, Nelson CD, Houtz DA, Xiao K, Madabushi S, Reiter E, Premont RT, Lichtarge O, and Lefkowitz RJ (2006) Beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor. J Biol Chem 281:1261-1273.
35. Takahashi Y, Kagawa Y, Izawa K, Ono R, Akagi M, and Kamei C (2009) Effect of histamine H4 receptor antagonist on allergic rhinitis in mice. Int Immunopharmacol 9:734-738.
36. Thurmond RL, Desai PJ, Dunford PJ, Fung-Leung WP, Hofstra CL, Jiang W, Nguyen S, Riley JP, Sun S, Williams KN, et al. (2004) A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties. J Pharmacol Exp Ther 309:404-413. (Pubitemid 38393154)
37. Vauquelin G and Charlton SJ (2010) Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. Br J Pharmacol 161:488-508.
38. Verdonk E, Johnson K, McGuinness R, Leung G, Chen Y, Tang HR, Michelotti JM, and Liu VF (2006) Cellular dielectric spectroscopy: a label-free comprehensive platform for functional evaluation of endogenous receptors. Assay Drug Dev Technol 4:609-619. (Pubitemid 46017404)
39. Waterfield A, Kinloch R, Williams R, Young T, Nickolls S (2009) The DiscoveRx PathHunter β-arrestin assay; a measure of agonist affinity? pA2online 3:001P.
40. Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyady L, Luttrell LM, and Lefkowitz RJ (2003) Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci USA 100:10782-10787. (Pubitemid 37140105)
41. 4 receptor: a novel modulator of inflammatory and immune disorders. Pharmacol Ther 113:594-606.